🇺🇸 FDA
Pipeline program

DEXAMETHASONE, ELRANATAMAB, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480

CA057-1040

Phase 2 small_molecule active

Quick answer

DEXAMETHASONE, ELRANATAMAB, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480 for Relapsed or Refractory Multiple Myeloma (RRMM) is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Relapsed or Refractory Multiple Myeloma (RRMM)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials